Scientists are already using AI in the lab. Not the heavily marketed "AI agents" that ELN vendors demo at trade shows, but the quiet, practical kind: asking ChatGPT to draft a protocol summary, using Copilot to clean up a data analysis script, running instrument data through a machine learning model to flag anomalies. It's happening in academic labs, in biotech startups, and in pharma R&D groups, often without any formal policy in place - and often without understanding what the implications could be.
The regulators have noticed. In the past two years, the FDA, EMA, MHRA, and ISPE have each published guidance that touches directly on AI in regulated research. None of it was written with the bench scientist in mind - the one wondering whether it's really OK to let ChatGPT draft a notebook entry. But the principles they establish have clear implications for exactly that scenario.
This is a plain-English summary of what the major regulatory bodies are saying about AI in the drug development lifecycle, what it means for scientists using AI tools in daily lab work, and what your lab should be doing now to stay on the right side of data integrity requirements.
The Regulatory Landscape: What's Been Published
The pace of regulatory activity around AI in life sciences has accelerated significantly since 2023. Here are the key documents that matter.
FDA Draft Guidance (January 2025): "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products"
This is the big one. Published on January 6, 2025, it's the FDA's first formal guidance on AI in drug and biologic development. The core framework is a seven-step risk-based credibility assessment for AI models used to generate data or information that supports regulatory decisions about safety, effectiveness, or quality. The seven steps walk sponsors through defining the question the AI addresses, specifying its context of use, assessing model risk based on "model influence" and "decision consequence," developing a credibility assessment plan, executing that plan, documenting results, and determining whether the model is adequate for its intended purpose.
Importantly, this guidance explicitly does not cover AI used purely for drug discovery, or for operational efficiencies - such as internal workflows, resource allocation, or drafting a regulatory submission - that do not impact patient safety, drug quality, or the reliability of nonclinical or clinical study results. It does cover AI used in nonclinical development, clinical trials, manufacturing, and post-marketing, and it makes clear that AI models in these contexts must meet the same evidentiary standards as any other analytical tool.
Source: FDA, "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products," January 2025. Docket No. FDA-2024-D-4689. Available at fda.gov.
EMA Reflection Paper (September 2024): "Reflection Paper on the Use of Artificial Intelligence (AI) in the Medicinal Product Lifecycle"
Finalized by the EMA's CHMP and CVMP in September 2024 after extensive public consultation, this paper provides the European perspective on AI across the entire medicines lifecycle, from drug discovery through post-authorization. The EMA takes a risk-based and human-centered approach, categorizing AI applications by their potential for "high patient risk" and "high regulatory impact." The paper emphasizes that existing GxP requirements - including GLP, GCP, and GMP - apply fully to AI-assisted processes. It explicitly states that AI models used in clinical trials should be pre-specified (fixed before study unblinding), and that AI used to determine treatment assignment or patient dosing represents a higher-risk application requiring more rigorous oversight.
The EMA also expects full documentation of AI systems: model architecture, training data, data processing pipelines, validation methodology, and performance monitoring plans. If an AI tool hasn't been previously qualified through EMA's Qualification of Novel Methodologies pathway, this documentation may be requested as part of the marketing authorization review.
Source: EMA, "Reflection Paper on the Use of Artificial Intelligence (AI) in the Medicinal Product Lifecycle," EMA/CHMP/CVMP/83833/2023, adopted September 2024. Available at ema.europa.eu.
Joint FDA-EMA Guiding Principles (January 2026): "Guiding Principles of Good AI Practice in Drug Development"
Published on January 14, 2026, this joint statement represents the most significant transatlantic regulatory alignment on AI to date. The FDA and EMA identified ten principles covering the full drug development lifecycle. Key themes include: AI must be human-centric by design with appropriate human oversight; it must be fit for purpose with clearly defined contexts of use; a risk-based approach should scale validation and controls to the system's impact; data governance must ensure quality, documentation, and transparency; and performance must be evaluated on an ongoing basis with periodic reviews.
The principles are directed at those developing medicines and marketing-authorization applicants and holders. While they're not formal binding requirements, both agencies have signaled these principles will underpin future guidance.
Source: FDA and EMA, "Guiding Principles of Good AI Practice in Drug Development," January 2026. Available at fda.gov and ema.europa.eu.
MHRA Strategic Approach (April 2024 and ongoing)
The UK's Medicines and Healthcare products Regulatory Agency published its strategic approach to AI in April 2024, aligning with the UK Government's five AI principles: safety and robustness, transparency and explainability, fairness, accountability and governance, and contestability and redress. The MHRA launched the AI Airlock in May 2024, a regulatory sandbox for AI-powered medical devices. The pilot phase completed in April 2025, with findings published to inform future UK AI medical device guidance. In September 2025, MHRA established a National Commission into the Regulation of AI in Healthcare, and opened a call for evidence in December 2025. While the MHRA's focus has been more on AI in medical devices than in lab documentation specifically, their data integrity guidance applying ALCOA+ principles is directly relevant to any AI use in GxP environments.
Source: MHRA, "Impact of AI on the Regulation of Medical Products," April 2024. Available at gov.uk.
ISPE GAMP Guide: Artificial Intelligence (July 2025)
The International Society for Pharmaceutical Engineering published this 290-page guide as the first comprehensive industry framework for validating AI in GxP environments. Developed by over 20 industry and academic experts, it extends the established GAMP 5 framework to cover AI-specific challenges including data governance, model lifecycle management, dynamic systems, and cybersecurity. The guide provides a framework for ensuring AI-enabled computerized systems are fit for purpose and compliant with relevant regulations, including 21 CFR Part 11 and EU Annex 11.
Source: ISPE, "GAMP Guide: Artificial Intelligence," published July 2025. Available at ispe.org.
What This Means for the Bench Scientist
None of these documents were written for someone wondering whether they can ask Claude to summarize their Western blot results. They're written for sponsors, manufacturers, and regulatory affairs professionals. But the underlying principles have clear practical implications for the daily realities of lab documentation - and here is how a reasonable compliance interpretation of that guidance maps to bench-level practice.
AI-generated content used in regulated records should be treated as part of those records
This is the foundational point. Under 21 CFR Part 11 and EU Annex 11, electronic records created or maintained to satisfy GxP and predicate rule requirements must be attributable, legible, contemporaneous, original, and accurate (the ALCOA principles). If AI-generated content is incorporated into documentation that serves those purposes - a notebook entry, a data analysis summary, an SOP section - that content is likely part of the controlled record and should be managed accordingly. Not every exploratory draft or scratch output automatically triggers Part 11, but any AI-assisted content that ends up in a required GxP record almost certainly does.
The scientist is responsible, not the AI
Every regulatory framework reviewed here frames AI as a tool, not an agent. The human who uses the AI tool owns the output. That means if an AI drafts a notebook entry and the scientist signs off on it, the scientist is attesting that the content is accurate, complete, and consistent with the underlying data.
Define which tasks are appropriate for AI assistance and which aren't
There's a meaningful difference between using AI to help draft a standard protocol summary and using it to interpret safety data. The FDA's risk framework provides a useful model: consider both the influence the AI has on the final output and the consequence if the output is wrong. Low-influence, low-consequence tasks (formatting, grammar, template population) carry less risk. High-influence, high-consequence tasks (interpreting clinical results, making stability determinations) warrant significantly more caution and oversight.
Document AI use as a prudent control
While no current guidance explicitly mandates that every AI-assisted notebook section carry a specific label, transparency about AI involvement is consistent with ALCOA's attribution principle and with the spirit of every regulatory framework published to date. A sensible control (and one that would serve you well in any inspection) is to note in the record that AI assistance was used, confirm who reviewed it, and record any modifications made. If your ELN supports metadata fields for this, use them. If not, a standard notation in each entry achieves the same purpose.
Don't let AI replace scientific judgment
This sounds obvious, but it's the failure mode regulators are most concerned about. AI is excellent at pattern matching, text generation, and data processing. It is not excellent at understanding why an experiment gave unexpected results, whether a protocol deviation matters, or whether a statistical anomaly reflects a real biological effect or an artifact. The scientist's expertise is the critical quality check. The EMA's reflection paper explicitly flags AI used to inform patient dosing or treatment decisions as high-risk territory requiring additional safeguards - and the same logic applies proportionally at the bench.
Validate AI tools used for data analysis
If you're using an AI or machine learning model for actual data analysis (not just text assistance but analytical processing) it should be validated for that purpose. The ISPE GAMP AI Guide provides a risk-based framework: define the intended use, assess the risk, validate performance against known standards, and monitor over time. The depth of validation should be proportionate to the risk.
Watch for hallucinations
Generative AI models can confidently produce plausible-sounding but incorrect code, references, or statistical interpretations. They may also confidently cite publications that don't exist. In a lab documentation context, this could mean invented references, incorrect calculations, fabricated data points, or plausible-sounding methods descriptions that don't match what was actually done. Every AI-generated output used in a GxP record should be verified against primary data before sign-off. The ISPE GAMP guide specifically identifies hallucination as a risk requiring mitigation in regulated environments.
Be prepared for inspection questions about AI
The FDA has made clear that AI-related documentation may be subject to review during inspections. That means sponsors should expect to demonstrate how AI is governed, validated, and overseen within their quality systems. Labs that have a written AI use policy, documented training, and clear audit trails are well positioned. Labs that have no record of having thought about any of this are not.
Where the Regulations Are Heading
Several things are clear from the trajectory of regulatory activity. First, more specific guidance is coming. The EU's GMP Annex 22 on AI in pharmaceutical manufacturing progressed to a consultation draft in 2025, with finalization targeted for Q4 2026. The current draft applies to static, deterministic AI and machine learning models used in critical GMP applications; dynamic, continually-learning systems and generative AI in those critical applications are explicitly out of scope for this first phase. The EMA is building on its reflection paper toward formal guidelines. The FDA's January 2025 draft guidance will be finalized. The joint FDA-EMA principles published in January 2026 signal that transatlantic alignment will continue to accelerate.
Second, the regulatory expectation is converging around a consistent set of themes: risk-based assessment, human oversight, data integrity, transparency, documentation, and lifecycle management. In general, these aren't really new concepts for regulated labs. They're merely extensions of principles that have been in place for decades under GxP frameworks. The challenge is applying them to a technology that evolves faster than regulatory guidance can be written.
Third, the bar for documentation is going to rise. As AI becomes more prevalent in lab work, regulators will expect more specific records of how AI contributed to research documentation and data analysis. Labs that build these habits now will have a significant advantage when formal requirements arrive.
The Bottom Line for Your Lab
AI is a legitimate and potentially valuable tool for lab documentation and data analysis. Regulators aren't trying to ban it. The FDA, EMA, and MHRA all acknowledge that AI can improve efficiency, reduce errors, and accelerate drug development. But they're also clear that AI doesn't get a free pass from existing quality and data integrity requirements.
The practical message from the regulatory landscape is this: use AI where it helps, document how you use it, review everything it produces, and maintain the scientific judgment that makes your records trustworthy. Using platforms like IGOR that were built to support compliance and data integrity can help you by providing a strong foundation for your research documentation practices. While AI governance is a new challenge; data integrity is not.
The labs that will navigate this well are the ones that establish clear policies now, before the regulations solidify and before an auditor asks the question. The technology is moving fast. The guidance is catching up. The smart move is to get ahead of both.
We'll dig into each of these regulations in more detail (and what they mean in practice) in the other posts in our AI in Research Documentation series.
References
- FDA, "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products," Draft Guidance, January 2025. Docket No. FDA-2024-D-4689. fda.gov
- EMA, "Reflection Paper on the Use of Artificial Intelligence (AI) in the Medicinal Product Lifecycle," EMA/CHMP/CVMP/83833/2023, adopted September 2024. ema.europa.eu
- FDA and EMA, "Guiding Principles of Good AI Practice in Drug Development," January 2026. fda.gov
- MHRA, "Impact of AI on the Regulation of Medical Products," April 2024. gov.uk
- ISPE, "GAMP Guide: Artificial Intelligence," July 2025. ispe.org
- FDA, "Artificial Intelligence and Medical Products: How CBER, CDER, CDRH, and OCP are Working Together," March 2024, revised February 2025. fda.gov
- EMA, "Artificial Intelligence Workplan to Guide Use of AI in Medicines Regulation." ema.europa.eu